Remove Clinical Development Remove Pharma Companies Remove Regulation
article thumbnail

Redx shares soar after IPF drug licence deal with AstraZeneca

pharmaphorum

The deal consisted of a $29m loan and a $1m investment and gave the company enough funding to carry on its R&D work into next year. The RXC006 deal makes sense for AstraZeneca, which has respiratory diseases as one of its main focus areas, although IPF is being targeted by other pharma companies too.

Drugs 109
article thumbnail

Novartis adds gene therapy for blindness with Gyroscope buy

pharmaphorum

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect. CFI regulates the activity of the complement immune system which is over-activated in GA. It has been fast-tracked by the FDA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

pharmaphorum

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98
article thumbnail

physIQ licenses virtual trial tech to Janssen in multi-year deal

pharmaphorum

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. The pharma company will use the technology known as accelerateIQ to collect data across its clinical studies through a variety of wearable biosensors.

article thumbnail

IQVIA’s report card for clinical trial diversity: must do better

pharmaphorum

While the numbers are disappointing, IQVIA’s report suggests there are signs of improvement, at least in the commitment of regulators, the pharma industry, payers and other stakeholders to do better.

article thumbnail

Patient involvement in trial design: looking to the future

pharmaphorum

That was the message from ‘The New Normal: Balancing the rapid evolution of trial design with patient need’ panel at the NIHR’s Clinical Research Network Virtual Event on Delivering Complex and Innovative Design (CID) Studies. Thankfully, many pharma companies seem to be gradually improving on this.

Trials 132
article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home.

Marketing 105